Long term tirofiban infusion before percutaneous coronary intervention in patients with angiographically massive intracoronary thrombus

Saudi Medical Journal

Volumn 29, Issue 1, 2008, Pages 42-47

  Timurkaynak, Timur ^a   Arslan, Ugur ^a   Balcioglu, Serhat ^a   Turkoglu, Sedat ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCERYL TRINITRATE; HEPARIN; TICLOPIDINE; TIROFIBAN; VERAPAMIL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TYROSINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG INFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATOMA; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TURKEY (REPUBLIC); CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NONPARAMETRIC TEST; RADIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TYROSINE;

EID: 40949142365     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Grines CL, Browne KF, Marco J, Rothbaum D. Stone GW, O'Keefe J, et al for The Primary Angioplasty in Myocardial Infarction Study Group, A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328: 673-679.
2. Stone GW, Grines, C.L. Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol 1995; 25: 370-377.
3. Brener SJ, Barr LA, Burchenal JE, Katz S. George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa. blockade with primary angioplasty for acute myocardial infarction, Circulation 1998; 98: 734-741.
4. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIB/IIIa receptor in high-risk coronary angioplasty: The EPIC Investigation. N Engl J Med 1994;330:956-961.
5. The RESTORE Investigators, Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Ciculation 1997; 96: 1445-1453.
6. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
7. van't Hof A, Liem A, Suryapranara H, Hoorntje JC, de Boer MJ Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Circulation 1998: 97: 2302-2306.
8. Morton JK, Joseph AM, Frank VA, Bath RG, Caracciolo EA, Wolford T, et al. Determination of angiographic. (TIMIGRADE) blood flow by intracoronary doppler flow velocity during acute myocardial infarction. Circulation 1996; 94: 1545-1552.
9. Piana RN, Paik GY, Mosucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
10. Marzilli M, Gliozheni E, Marraccini P, Fedele S. Primary coronary angioplasty in acute myocardial infarction.: Clinical correlates of the "no reflow" phenomenon. Int J Candiol 1998; 65 (Suppl 1): 523-528.
11. Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995; 130: 239-243.
12. Waller BF, Fry E, Peters TF, Hermiller JB, Orr CM, Van'Tassel J, et al. Abrupt: (< 1 day), acute (<1 week) and early (< 1 month) vessel closure at the angioplasty site: Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty. Clin Cardiol 1996; 19: 857-868.
13. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, et al. The effect of intravenous thrombolytic therapy on left ventricular funcOion: A report: on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI) phase I trial. Circulation 1987; 72: 817-829.
14. The TIMI IIIA Investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients prcsenting with ischemic cardiac pain at rest. Circulation 1993, 87: 38-52.
15. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Arderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: 1045-1051.
16. Miller JM, Ohman EM, Schildcrour JS, Smalling RW, Betriu A, Califf RM, et al. Survival benefit of abciximab administration during early rescue angioplasty: Analysis of 387 patients from the GUSTO III trial. J Am Coll Cardiol 1998; 31: 191A.
17. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ. Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997; 95: 1755-1759.
18. Zhao XQ, Theroux P, Snapinn SM, Sax FL for the PRISM-PLUS Investigators. Intracoronary Thrombus and Platelet Glycoprotein IIb/IIIa Receptor Blockade with Tirofiban in Unstable Angina or Non-Q-Wave Myocardial Infarction. Circulation 1999; 100: 1609-1615.
19. Bailey SR, O'Leary E, Chiton R. Angioscopic evaluation of site-specific administration of ReoPro. Cathet Cardiovasc Diagn 1997; 42: 181-184.
20. Deng G, Royle G, Seiffert D, Loskutoff DJ. The PAI-I/vitronectin interaction: Two cats in the bag? Thromb Haemost 1995; 74: 66-70.
21. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptors in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
22. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957-966.
23. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, et al. Restoration of coronary flow in myocardial infarction by intraveneous chimeric 7E3 antibody without exogenous plasminogen activators. Circulation 1997; 95: 1755-1759.
24. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, et al. TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMi 14 substudy. Circulation 2001; 103: 2550-2554.
25. Neuman FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
26. Yip HK, Wu CJ, Chang HW, Hsieh YK, Fang CY, Chen SM, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes. Chest 2003; 124: 962-968.
27. Fujii T, Ueda M, Ikura Y, Osawa M, Kawano S, Ito H, et al. Aspiration intracoronary thrombus by Rescue FT catheter: Histological and immunohistochemical analyses (abstract). Circulation 2002.; 66 (suppl 1): 458.
28. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, et al; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY timing trial. JAMA 2007; 297: 591-602.
29. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344: 1888-1894.